Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CT Scan Study Design Is Among OST Director Kessler’s Sabbatical Activities

This article was originally published in The Gray Sheet

Executive Summary

Office of Science & Technology Director Larry Kessler, PhD, designed a study on use of computed tomography scanning during his stint at the Fred Hutchinson Cancer Research Center in Seattle

You may also be interested in...



CDRH’s Marlowe To Coordinate FDA Science Standards; Kessler Will Head OST

Donald Marlowe, director of the Office of Science & Technology at the device center since April 1995, stepped into the newly created position of standards administrator for FDA's Office of Science & Health Coordination Oct. 7

Spiral CT Will Be Compared With Chest X-Ray In NCI Lung Screening Trial

Enrollment in a National Cancer Institute-sponsored lung screening trial comparing spiral CT to chest x-ray will be complete in one to two years, NCI says

FDA Biometrics Chief: Mammogram Double Readings Should Be U.S. Policy

The receiver operating characteristic (ROC) curve associated with radiologists' detection of breast cancers should be analyzed through a "contemporary" study of mammography variability, according to CDRH Office of Surveillance & Biometrics Director Larry Kessler

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel